TY - JOUR
T1 - Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries
AU - Omata, Masao
AU - Kanda, Tatsuo
AU - Yokosuka, Osamu
AU - Crawford, Darrell
AU - Al-Mahtab, Mamun
AU - Wei, Lai
AU - Ibrahim, Alaaeldin
AU - Lau, George K.K.
AU - Sharma, Barjesh C.
AU - Hamid, Saeed S.
AU - Chuang, Wan Long
AU - Dokmeci, A. Kadir
N1 - Funding Information:
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study. This article does not contain any studies with animal subjects. Masao Omata, Mamun Al-Mahtab, Alaaeldin Ibrahim, George K.K. Lau, Barjesh C. Sharma, Saeed S. Hamid and A. Kadir Dokmeci declare that they have no conflict of interest. Tatsuo Kanda has research grants from Chugai Pharmaceutical, MSD, Sumitomo Dainippon Pharma and Bristol-Myers Squibb, and reports receiving lecture fees from Chugai Pharmaceutical, MSD, Tanabe-Mitsubishi, Ajinomoto, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen Pharmaceutical and GlaxoSmithKline. Osamu Yokosuka has research grants from Chugai Pharmaceutical, Bayer, MSD, Daiichi-Sankyo, Tanabe-Mitsubishi, Bristol-Myers Squibb and Gilead. Darrell Crawford is a member of the national and international advisory board of Abbvie and a national advisory board member of Gilead and Jansen Cilag. Lai Wei has research grants from Bristol-Myers Squibb and reports receiving consulting fees from Abbvie and Gilead. Wan-Long Chuang is a member of the advisory boards of Abbvie, BI, Gilead, Novartis and Roche and is a speaker for BMS, Gilead, MSD and Roche.
Publisher Copyright:
© 2015, Asian Pacific Association for the Study of the Liver.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Estimated hepatitis C virus (HCV) infection rates in the general populations were 1.3, 0.9, 0.4–1.0, 14.7, 0.1–0.3, 0.9–1.9, 1.0–2.0, 5, 4.4–8.6 and 0.5–1.3 % in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. The main HCV genotypes (Gs) are G1, G3, G1b, G4, G1b, G3, G1b, G3, G1b and G2, and G1 in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. Of IL28B genotypes, favorable alleles are ~50 % in Australia and Turkey, but 60–70 % in most of the other Asian countries. Peginterferon plus ribavirin is available in all ten Asian Pasific countries. In addition, HCV NS3/4A protease inhibitors with peginterferon plus ribavirin are currently available in several countries. Clinical trials of interferon-free regimens for HCV are ongoing in most of the ten Asian Pacific countries.
AB - Estimated hepatitis C virus (HCV) infection rates in the general populations were 1.3, 0.9, 0.4–1.0, 14.7, 0.1–0.3, 0.9–1.9, 1.0–2.0, 5, 4.4–8.6 and 0.5–1.3 % in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. The main HCV genotypes (Gs) are G1, G3, G1b, G4, G1b, G3, G1b, G3, G1b and G2, and G1 in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. Of IL28B genotypes, favorable alleles are ~50 % in Australia and Turkey, but 60–70 % in most of the other Asian countries. Peginterferon plus ribavirin is available in all ten Asian Pasific countries. In addition, HCV NS3/4A protease inhibitors with peginterferon plus ribavirin are currently available in several countries. Clinical trials of interferon-free regimens for HCV are ongoing in most of the ten Asian Pacific countries.
KW - Asian Pacific countries
KW - Direct-acting antivirals
KW - HCV
KW - IL28B
UR - http://www.scopus.com/inward/record.url?scp=84944513786&partnerID=8YFLogxK
U2 - 10.1007/s12072-015-9630-4
DO - 10.1007/s12072-015-9630-4
M3 - Review article
C2 - 25941137
AN - SCOPUS:84944513786
SN - 1936-0533
VL - 9
SP - 486
EP - 507
JO - Hepatology International
JF - Hepatology International
IS - 4
ER -
